ANTX
Income statement / Annual
Last year (2024), AN2 Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, AN2 Therapeutics, Inc.'s net income was -$51.32 M.
See AN2 Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
-$77.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$40.49 M
|
$54.87 M
|
$29.51 M
|
$16.91 M
|
$6.02 M
|
$4.89 M
|
| General & Administrative Expenses |
$0.00
|
$14.76 M
|
$12.75 M
|
$4.67 M
|
$1.27 M
|
$1.73 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$287.27 K
|
| Selling, General & Administrative Expenses |
$14.07 M
|
$14.76 M
|
$12.75 M
|
$4.67 M
|
$1.27 M
|
$289.00 K
|
| Other Expenses |
$2.23 M
|
$0.00
|
-$45.00 K
|
-$38.00 K
|
-$6.32 M
|
$0.00
|
| Operating Expenses |
$54.55 M
|
$69.64 M
|
$42.26 M
|
$21.57 M
|
$7.28 M
|
$5.18 M
|
| Cost And Expenses |
$56.79 M
|
$69.64 M
|
$42.26 M
|
$21.57 M
|
$7.28 M
|
$5.18 M
|
| Interest Income |
$5.47 M
|
$0.00
|
$1.35 M
|
$69.00 K
|
$3.00 K
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$514.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$69.64 M
|
$77.00 K
|
$21.57 M
|
$7.28 M
|
$31.07 M
|
| EBITDA |
-$51.32 M |
$4.90 M |
-$42.26 M |
-$21.57 M |
-$6.32 M |
$0.00 |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$3.23 M
|
$4.90 M
|
$1.31 M
|
$31.00 K
|
-$6.32 M
|
-$457.00 K
|
| Income Before Tax |
-$51.32 M
|
-$64.73 M
|
-$40.96 M
|
-$21.54 M
|
-$13.60 M
|
-$5.64 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$514.00 K
|
-$69.00 K
|
-$3.00 K
|
-$31.07 K
|
| Net Income |
-$51.32 M
|
-$64.73 M
|
-$40.96 M
|
-$21.54 M
|
-$13.60 M
|
-$5.64 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.72 |
-2.74 |
-2.79 |
-1.55 |
-0.97 |
-0.3 |
| EPS Diluted |
-1.72 |
-2.74 |
-2.79 |
-1.55 |
-0.97 |
-0.3 |
| Weighted Average Shares Out |
$29.83 M
|
$23.60 M
|
$15.34 M
|
$18.74 M
|
$18.74 M
|
$18.74 M
|
| Weighted Average Shares Out Diluted |
$29.83 M
|
$23.60 M
|
$15.34 M
|
$18.74 M
|
$18.74 M
|
$18.74 M
|
| Link |
|
|
|
|
|
|
